Lokon Pharma receives FDA Fast Track Designation for LOAd703 for the treatment of Pancreatic Cancer
Lokon's first clinical product, LOAd703, was granted Fast Track Designation in the U.S. by the FDA for the treatment of pancreatic cancer. LOAd703 is a gene engineering viral vector, a form of immunotherapy, which has shown promising results in early studies. Fast Track will support clinical development as meetings with the FDA can occur more frequently.